10x Genomics (TXG) Cash from Operations (2018 - 2026)

10x Genomics has disclosed Cash from Operations across 9 years of filings, most recently posting $17.0 million for Q2 2026.

• In Q2 2026, Cash from Operations fell 4.15% year-over-year to $17.0 million; the TTM figure through Jun 2026 stood at $127.1 million (up 89.82% YoY), while the FY2025 annual figure was $136.0 million, up 1941.57% from the prior year.
• Cash from Operations came in at $17.0 million for Q2 2026 at 10x Genomics, down from $26.1 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $43.2 million in Q3 2025 to a low of -$25.3 million in Q3 2023.
• Average Cash from Operations over 5 years is $7.6 million, with a median of $10.6 million recorded in 2022.
• Year-over-year, Cash from Operations sank 643.69% in 2022 and jumped 704.28% in 2025.
• Over 5 years, Cash from Operations stood at $13.7 million in 2022, then surged by 87.7% to $25.8 million in 2023, then tumbled by 126.2% to -$6.7 million in 2024, then jumped by 704.28% to $40.8 million in 2025, then plunged by 58.37% to $17.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were $17.0 million in Q2 2026, $26.1 million in Q1 2026, and $40.8 million in Q4 2025.